ZENAS BIOPHARMA ANNOUNCES UPCOMING PRESENTATIONS OF ORELABRUTINIB DATA IN RELAPSING REMITTING MULTIPLE SCLEROSIS, CLINICAL TRIAL DESIGNS IN PROGRESSIVE MULTIPLE SCLEROSIS AND OTHER MULTIPLE SCLEROSIS PORTFOLIO DATA AT MSTORONTO2026

Reuters · 1d ago

Please log in to view news